Crispr Therapeutics AG (CRSP) Price & Analysis

Compare

10,209 Followers

CRSP Stock Chart & Stats

Day’s Range― - ―

52-Week Range$30.04 - $71.13

Previous CloseN/A

Volume437.82K

Average Volume (3M)3.19M

Market Cap

$4.71B

Enterprise Value$2.73B

Total Cash (Recent Filing)$1.72B

Total Debt (Recent Filing)$215.45M

Price to Earnings (P/E)―

Beta2.16

Next Earnings

Oct 29, 2025

EPS Estimate

-1.24

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.40

Shares Outstanding90,950,424

10 Day Avg. Volume1,898,511

30 Day Avg. Volume3,185,108

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.58

Enterprise Value/Revenue72.96

Enterprise Value/Gross Profit-33.63

Enterprise Value/Ebitda-5.33

Forecast

1Y Price Target

$70.00

Price Target Upside35.06% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering18

Bulls Say, Bears Say

Bulls Say

Clinical TrialsImpressive topline results for CTX310 demonstrated reductions of up to 82% in triglycerides, and 86% in LDL from baseline in high-risk patients.

Financial PerformanceCasgevy sales reached $30.4mm, surpassing expectations and showing strong performance in the market.

Global ExpansionCRISPR Therapeutics has reached the target activation of 75 authorized treatment centers globally, which is expected to further catalyze growth.

Bears Say

EarningsCRISPR Therapeutics recorded a net loss of $2.38 per share, which was significantly wider than the prior estimate.

Pipeline ValidationBears argue pipeline validation is needed to justify further upside, indicating skepticism about future performance.

R&D SpendingR&D spending was below expectations, which might raise concerns about future development progress.

Crispr Therapeutics AG News

Cathie Wood Buys the Dip in Bitmine Stock, Continues Dumping Roku and DraftKings

Ace hedge fund manager Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made notable portfolio adjustments on Wednesday, August 27, according to the...

3d ago

ARKF

ARKK

Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!

Investors seeking all of the latest stock market news for Wednesday will find it in in the TipRanks daily wrap-up. ...

4d ago

AHL

Cathie Wood’s ARK Investment buys 124K shares of Crispr Therapeutics today

20:06 EDT Cathie Wood’s ARK Investment buys 124K shares of Crispr Therapeutics (CRSP) today Published first on TheFly...

4d ago

CRSP

Cathie Wood Adds Over $11M in Biotech Stocks, Reduces Stakes in Roku and DraftKings

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) executed a series of trades on Tuesday, August 26, 2025, according to the...

4d ago

COIN

CRSP

Cathie Wood Continues to Sell Roku, Invests $13M in CRISPR and Intellia

Ace hedge fund manager Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made a few but notable portfolio adjustments on Monday, August...

5d ago

Cathie Wood’s ARK Investment buys 189K shares of Crispr Therapeutics today

20:08 EDT Cathie Wood’s ARK Investment buys 189K shares of Crispr Therapeutics (CRSP) today Published first on TheFly...

6d ago

CRSP

Cathie Wood Sells Roku Stock, Doubles Down on Biotech Bets

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made strategic portfolio adjustments on Wednesday, August 20, according to the funds’ daily disclosures....

10d ago

TXG

Cathie Wood ‘Buys the Dip’ in Robinhood, CRISPR, and Beam Therapeutics Stocks

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made significant multi-million-dollar trades in the fintech and biotech sectors on Tuesday, August 19,...

11d ago

TXG

WGS

Cathie Wood Pours Over $46M into Biotech Stocks, 8/19/2025

12d ago

WGS

BEAM

CRWV and RBLX: Cathie Wood Invests Over $27 Million in Tech Stocks

15d ago

CRSP

CRWV

Crispr Therapeutics price target raised to $12 from $10 at Barclays

Barclays raised the firm’s price target on Crispr Therapeutics (CRSP) to $12 from $10 and keeps an Overweight...

23d ago

CRSP

Cathie Wood’s ARK Investment buys 181.3K shares of Crispr Therapeutics today

20:13 EDT Cathie Wood’s ARK Investment buys 181.3K shares of Crispr Therapeutics (CRSP) today Published first on TheFly...

26d ago

CRSP

Closing Bell Movers: Palantir hits record highs on beat and raise

In the opening hour of the evening session, U.S. equity futures are up marginally, with S&P 500, Nasdaq...

27d ago

Crispr Therapeutics reports Q2 EPS ($2.40), consensus ($1.40)

Reports Q2 revenue $892,000, consensus $6.44M. “We are entering the second half of the year with momentum across...

27d ago

CRSP

CRSP FAQ

What was Crispr Therapeutics AG’s price range in the past 12 months?

Crispr Therapeutics AG lowest stock price was $30.04 and its highest was $71.13 in the past 12 months.

What is Crispr Therapeutics AG’s market cap?

Crispr Therapeutics AG’s market cap is $4.71B.

When is Crispr Therapeutics AG’s upcoming earnings report date?

Crispr Therapeutics AG’s upcoming earnings report date is Oct 29, 2025 which is in 59 days.

How were Crispr Therapeutics AG’s earnings last quarter?

Crispr Therapeutics AG released its earnings results on Aug 04, 2025. The company reported -$2.4 earnings per share for the quarter, missing the consensus estimate of -$1.402 by -$0.998.

Is Crispr Therapeutics AG overvalued?

According to Wall Street analysts Crispr Therapeutics AG’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Crispr Therapeutics AG pay dividends?

Crispr Therapeutics AG does not currently pay dividends.

What is Crispr Therapeutics AG’s EPS estimate?

Crispr Therapeutics AG’s EPS estimate is -1.24.

How many shares outstanding does Crispr Therapeutics AG have?

Crispr Therapeutics AG has 90,950,424 shares outstanding.

What happened to Crispr Therapeutics AG’s price movement after its last earnings report?

Crispr Therapeutics AG reported an EPS of -$2.4 in its last earnings report, missing expectations of -$1.402. Following the earnings report the stock price went down -6.713%.

Which hedge fund is a major shareholder of Crispr Therapeutics AG?

Currently, no hedge funds are holding shares in CRSP

Crispr Therapeutics AG Stock Smart Score

Neutral

Fundamentals

Return on Equity

-25.34%

Trailing 12-Months

Asset Growth

-13.25%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Crispr Therapeutics AG

Crispr Therapeutics AG is a biotechnology company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing technology. Established in 2013 and headquartered in Zug, Switzerland, the company operates primarily in the fields of hematology, immuno-oncology, and regenerative medicine. Its core products include CTX001, a treatment for beta-thalassemia and sickle cell disease, and various other therapies targeting genetic disorders and cancer.

Crispr Therapeutics AG (CRSP) Earnings & Revenues

Historic Earnings Reports

CRSP Stock 12 Month Forecast

Average Price Target

$70.00

▲(35.06% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"32":"$32","69":"$69","106":"$106","50.5":"$50.5","87.5":"$87.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$105.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[32,50.5,69,87.5,106],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.09,59.8523076923077,63.61461538461539,67.37692307692308,71.13923076923078,74.90153846153846,78.66384615384615,82.42615384615385,86.18846153846154,89.95076923076923,93.71307692307693,97.47538461538461,101.2376923076923,{"y":105,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.09,57.160000000000004,58.230000000000004,59.300000000000004,60.370000000000005,61.440000000000005,62.510000000000005,63.58,64.65,65.72,66.79,67.86,68.93,{"y":70,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.09,54.8523076923077,53.61461538461539,52.37692307692308,51.13923076923077,49.901538461538465,48.66384615384616,47.42615384615385,46.18846153846154,44.95076923076923,43.713076923076926,42.47538461538461,41.23769230769231,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":53.95,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.85,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.58,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.76,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.36,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.59,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.73,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.95,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.09,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >